



- (51) International Patent Classification:  
*C12M 1/12* (2006.01) *B01D 39/14* (2006.01)
- (21) International Application Number:  
PCT/US2013/063480
- (22) International Filing Date:  
4 October 2013 (04.10.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/709,891 4 October 2012 (04.10.2012) US
- (71) Applicant: IMMUNOGEN, INC. [US/US]; 830 Winter Street, Waltham, Massachusetts 02451-1477 (US).
- (72) Inventors: CHEN, Xiaoxi Kevin; 76A Rathbun Road, Natick, Massachusetts 01760 (US). LI, Xinfang; 85 Brookline Street, Newton, Massachusetts 02467 (US).
- (74) Agents: DISE, Rebecca S. et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, Chicago, Illinois 60601-6731 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES




FIG. 1A

(57) Abstract: The invention provides processes for preparing purified cell-binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell-binding agent cytotoxic agent conjugate and one or more impurities to a polyvinyl difluoride (PVDF) membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell-binding agent cytotoxic agent conjugate.